Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets.
Abivax Announces Results of its May 11, 2026 Annual General Meeting Abivax Announces Results of its May 11, 2026 Annual General Meeting
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
Abivax to Present Data on Obefazimod at Digestive Disease Week® Abivax to Present Data on Obefazimod at Digestive Disease Week®
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
Goldman Sachs Bullish Forecast: 15% Increase in 2026 U.S. M&A Activity As the first quarter of 2026 comes to a close, the financial world is buzzing with a renewed sense of optimism. Goldman Sachs (
NYSE: GS ) has released its highly anticipated 2026 Global M&A Outlook, titled "Think Big, Build Bigger," predicting a massive 15% increase in merger and acquisition deal
2 Healthcare Stocks to Buy Before They Get Bought Out Abivax and Nektar Therapeutics are clinical-stage biotech companies that would make attractive buyout targets.
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.
